On Nov. 19, 2020, F4 Pharma announced the inclusion of the first patient with severe COVID-19 in a study named ﾓFX-COVIDﾔ. The randomized, double-blind, placebo-controlled FX-COVID trial was conducted by AP-HP (Assistance Publique ﾖ Hopitaux de Paris) in France, to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.

The study included four intensive care units and is sponsored by AP-HP, the University hospital trust operating in Paris and its surroundings, being the largest hospital system in Europe.